AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10714911 — intervention group
Group type: COMPARATOR
Intervention: Treatment-free control group (Group C)
Number of subjects: 120
Study 9468004 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 24
Study 9468004 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study 8176626 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine (200 mg daily)
Number of subjects: 151
Study 8176626 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 151
Study 3513533 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual snacks (milk chocolate bar, granola bar, chocolate milk, peanut butter cups, yogurt, potato chips)
Number of subjects: 0
Study 3513533 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric snack meals (cereal-milk, cheese sandwich-milk, peanut butter sandwich-chocolate milk)
Number of subjects: 0
Study 3513533 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual snacks
Number of subjects: 0
Study 30024220 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure (EX) condition
Number of subjects: 70
Study 30024220 — intervention group
Group type: COMPARATOR
Intervention: Nonexposure condition
Number of subjects: 70
Study 28185784 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Neurocognitive Therapy (INT)
Number of subjects: 61
Study 28185784 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 61
Study 24972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality reminders
Number of subjects: 112
Study 24972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem threats
Number of subjects: 112
Study 24972015 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing device
Number of subjects: 112
Study 23932548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 2591
Study 23932548 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2591
Study 21307816 — intervention group
Group type: COMPARATOR
Intervention: baclofen (10 mg)
Number of subjects: 44
Study 21307816 — intervention group
Group type: COMPARATOR
Intervention: meclizine (50 mg)
Number of subjects: 44
Study 21307816 — intervention group
Group type: COMPARATOR
Intervention: cinnarizine (20 mg) + dimenhydrinate (40 mg)
Number of subjects: 44
Study 21307816 — intervention group
Group type: COMPARATOR
Intervention: promethazine (25 mg) + dextro‐amphetamine (5 mg)
Number of subjects: 44
Study 21307816 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 20368225 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training program (rowing ergometry at 65-70% of peak oxygen uptake) for 8 weeks
Number of subjects: 25
Study 20368225 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 25
Study 16950962 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg)
Number of subjects: 35
Study 16950962 — intervention group
Group type: COMPARATOR
Intervention: Mixed amphetamine salts extended release (30 mg)
Number of subjects: 35
Study 16950962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 15597521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1000 mg qd
Number of subjects: 134
Study 15597521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) 1500 mg qd
Number of subjects: 134
Study 15597521 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) monotherapy
Number of subjects: 134
Study 15597521 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) alone
Number of subjects: 134
Study 15597521 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ddI plus HU
Number of subjects: 134
Study 15597521 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 134
Study 11374699 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ursodeoxycholic acid (UDCA) 25-30 mg/kg per day
Number of subjects: 30
Study 11374699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9018022 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (3 mg)
Number of subjects: 0
Study 9018022 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (150 mg)
Number of subjects: 0
Study 9018022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (300 mg)
Number of subjects: 0
Study 9018022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8329266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal tube cuff inflated
Number of subjects: 20
Study 8329266 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube cuff deflated
Number of subjects: 20
Study 3525023 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068 (150 mg)
Number of subjects: 12
Study 3525023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg)
Number of subjects: 12
Study 3525023 — intervention group
Group type: EXPERIMENTAL
Intervention: PY 108-068 (75 mg)
Number of subjects: 12
Study 3525023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30077754 — intervention group
Group type: EXPERIMENTAL
Intervention: Grayscale inversion view
Number of subjects: 162
Study 30077754 — intervention group
Group type: COMPARATOR
Intervention: Standard view
Number of subjects: 162
Study 27138643 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS-Matching
Number of subjects: 22
Study 27138643 — intervention group
Group type: COMPARATOR
Intervention: tDCS-Resting
Number of subjects: 22
Study 24871787 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9601 (60 mg, thrice daily)
Number of subjects: 520
Study 24871787 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (200 μg, thrice daily)
Number of subjects: 520
Study 24871787 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9601
Number of subjects: 520
Study 24871787 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 520
Study 22730052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice slurry (−1.4°C; ICE)
Number of subjects: 12
Study 22730052 — intervention group
Group type: COMPARATOR
Intervention: Ambient temperature drink (30.9°C; CON)
Number of subjects: 12
Study 20537558 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine patch (1.5 mg)
Number of subjects: 74
Study 20537558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 18237269 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-microg dose of H5N1 influenza vaccine
Number of subjects: 337
Study 18237269 — intervention group
Group type: EXPERIMENTAL
Intervention: 45-microg dose of H5N1 influenza vaccine
Number of subjects: 337
Study 18237269 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-microg dose of H5N1 influenza vaccine
Number of subjects: 337
Study 18237269 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5-microg dose of H5N1 influenza vaccine
Number of subjects: 337
Study 18237269 — intervention group
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine (third dose)
Number of subjects: 337
Study 15457206 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/benazepril HCl
Number of subjects: 0
Study 15457206 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril HCl/hydrochlorothiazide
Number of subjects: 0
Study 12830564 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help intervention based on cognitive behaviour principles in general practice.
Number of subjects: 68
Study 12830564 — intervention group
Group type: COMPARATOR
Intervention: Specialist outpatient treatment in specialist eating disorder clinics.
Number of subjects: 68
Study 10397217 — intervention group
Group type: COMPARATOR
Intervention: Standard Arrow catheter
Number of subjects: 120
Study 10397217 — intervention group
Group type: COMPARATOR
Intervention: ARROWgard catheter
Number of subjects: 120
Study 10397217 — intervention group
Group type: COMPARATOR
Intervention: Bio-Guard catheter
Number of subjects: 120
Study 8723805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0
Study 1512689 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) treatment
Number of subjects: 0
Study 6542866 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin
Number of subjects: 8
Study 6542866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31283835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative CRP ≥5 mg/dL
Number of subjects: 314
Study 31283835 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative CRP
Number of subjects: 314
Study 28132701 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT intervention (screening, brief intervention, and referral to treatment)
Number of subjects: 732
Study 28132701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SBIRT intervention)
Number of subjects: 732
Study 28132701 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT intervention
Number of subjects: 732
Study 28132701 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study 27266498 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time tissue elastography
Number of subjects: 126
Study 27266498 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D contrast-enhanced ultrasonography (CEUS)
Number of subjects: 126
Study 27266498 — intervention group
Group type: EXPERIMENTAL
Intervention: Two joint inspection
Number of subjects: 126
Study 24879388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) with 25g glucose
Number of subjects: 16
Study 24879388 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous glucose infusion (IIGI)
Number of subjects: 16
Study 24879388 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) with 75g and 125g glucose
Number of subjects: 16
Study 22002325 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA
Number of subjects: 0
Study 22002325 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 0
Study 22002325 — intervention group
Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA
Number of subjects: 0
Study 19101598 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based weight loss intervention (four 2-hour workshops)
Number of subjects: 62
Study 19101598 — intervention group
Group type: COMPARATOR
Intervention: Control (normal diet)
Number of subjects: 62
Study 17240248 — intervention group
Group type: EXPERIMENTAL
Intervention: Residents-as-teachers program (10.5-hour workshop)
Number of subjects: 24
Study 17240248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 15230100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquitous biotherapy in 40 patients
Number of subjects: 70
Study 15230100 — intervention group
Group type: COMPARATOR
Intervention: Control group treated according to generally accepted principles (30 patients)
Number of subjects: 70
Study 11772900 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes medication or weight-reduction program for patients with IGT
Number of subjects: 3638
Study 11772900 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 3638
Study 9682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia
Number of subjects: 90
Study 9682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia plus systemic metronidazole (200 mg tds for 7 days)
Number of subjects: 90
Study 9682550 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival scaling using ultrasonic scalers and local anaesthesia plus two applications of 25% metronidazole gel one week apart
Number of subjects: 90
Study 9234259 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I‐B72.3 (1 mg)
Number of subjects: 10
Study 9234259 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I‐B72.3 (20 mg)
Number of subjects: 10
Study 9234259 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐CC49 (1 mg)
Number of subjects: 10
Study 9234259 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐CC49 (20 mg)
Number of subjects: 10
Study 2920999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (15 mg intravenous single dose)
Number of subjects: 16
Study 2920999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg per day chronic oral administration)
Number of subjects: 16
Study 2920999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 mg intravenous single dose)
Number of subjects: 16
Study 2920999 — intervention group
Group type: COMPARATOR
Intervention: Placebo (160 mg per day chronic oral administration)
Number of subjects: 16
Study 2920999 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Placebo
Number of subjects: 16
Study 31689007 — intervention group
Group type: COMPARATOR
Intervention: WL (Weight Loss)
Number of subjects: 222
Study 31689007 — intervention group
Group type: COMPARATOR
Intervention: WL + AT (Weight Loss plus Aerobic Training)
Number of subjects: 222
Study 31689007 — intervention group
Group type: COMPARATOR
Intervention: WL + RT (Weight Loss plus Resistance Training)
Number of subjects: 222
Study 28062685 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive scoring model for all-cause 30 day mortality based on logistic regression including factors such as age >50 years, infection due to Klebsiella spp., source other than urinary tract, fatal underlying disease, Pitt score >3, severe sepsis or septic shock at presentation, and inappropriate early targeted therapy.
Number of subjects: 950
Study 26193907 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnership-based self-management programme
Number of subjects: 100
Study 26193907 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 100
Study 23914988 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone 500 mg twice daily
Number of subjects: 0
Study 23914988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21565593 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological treatment (PT), 10 sessions, manualized, individually-administered
Number of subjects: 38
Study 21565593 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysiological treatment (PT)
Number of subjects: 38
Study 21565593 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care augmented by psychiatric consultation (wait-list)
Number of subjects: 38
Study 19593170 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided standardized stepwise drug treatment regimen (SSTR)
Number of subjects: 148
Study 19593170 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 148
Study 17227922 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 104
Study 17227922 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitors (optimized medical therapy)
Number of subjects: 104
Study 12478127 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy and flutamide
Number of subjects: 1076
Study 12478127 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy and placebo
Number of subjects: 1076
Study 10898413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary beta-radiation
Number of subjects: 120
Study 10898413 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-irradiated patients in BERT)
Number of subjects: 120
Study 10898413 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-irradiated patients)
Number of subjects: 120
Study 10898413 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 8817407 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg, sublingual)
Number of subjects: 28
Study 8817407 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 28
Study 1422288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine containing 1:80,000 epinephrine
Number of subjects: 19
Study 1422288 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine containing 1:25,000 norepinephrine
Number of subjects: 19
Study 4059722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 845
Number of subjects: 0
Study 4059722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentry
Number of subjects: 0
Study 4059722 — intervention group
Group type: COMPARATOR
Intervention: Mercury sphygmomanometer
Number of subjects: 0
Study 4059722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap (during emotional pressor response assessment)
Number of subjects: 0
Study 2897305 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bisoprolol
Number of subjects: 40
Study 2897305 — intervention group
Group type: COMPARATOR
Intervention: 50 mg hydrochlorothiazide plus 5 mg amiloride
Number of subjects: 40
Study 31823111 — intervention group
Group type: EXPERIMENTAL
Intervention: SUP mobile app
Number of subjects: 0
Study 31823111 — intervention group
Group type: COMPARATOR
Intervention: No-treatment condition (control)
Number of subjects: 0
Study 29533751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy (TE) in childhood
Number of subjects: 132
Study 29533751 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched individuals)
Number of subjects: 132
Study 28992467 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg daily rosuvastatin
Number of subjects: 0
Study 28992467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28992467 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ADMA (highest tertile)
Number of subjects: 0
Study 28992467 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin randomization
Number of subjects: 0
Study 26120980 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclosan in combination with standard therapy
Number of subjects: 103
Study 26120980 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 103
Study 23020859 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimized perfusion circuit (MPC)
Number of subjects: 28
Study 23020859 — intervention group
Group type: COMPARATOR
Intervention: Conventional circulatory perfusion bypass (CCPB)
Number of subjects: 28
Study 21940214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rituximab
Number of subjects: 823
Study 21940214 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 823
Study 21940214 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rituximab (favourable subgroup, IPI=0, no bulk)
Number of subjects: 823
Study 21940214 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (less favourable subgroup, IPI=1 or bulk, or both)
Number of subjects: 823
Study 19069803 — intervention group
Group type: EXPERIMENTAL
Intervention: Magneto-laser therapy
Number of subjects: 75
Study 19069803 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity laser therapy
Number of subjects: 75
Study 19069803 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 75
Study 16997055 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative team model (INT)
Number of subjects: 223
Study 16997055 — intervention group
Group type: COMPARATOR
Intervention: Usual physician-managed care (UC)
Number of subjects: 223
Study 13130087 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials published in podiatric medical journals
Number of subjects: 0
Study 13130087 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials published in a mainstream medical journal
Number of subjects: 0
Study 11008052 — intervention group
Group type: EXPERIMENTAL
Intervention: Acular (ketorolac tromethamine 0.5%)
Number of subjects: 26
Study 11008052 — intervention group
Group type: COMPARATOR
Intervention: Ocufen (flurbiprofen sodium) preoperatively and Pred Forte (prednisolone acetate 1%) postoperatively
Number of subjects: 26
Study 8630720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 micrograms bid for 16 weeks
Number of subjects: 96
Study 8630720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1000 micrograms bid for 1 year (open-label)
Number of subjects: 96
Study 8630720 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 96
Study 8630720 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate after switching from placebo during open-label period
Number of subjects: 96
Study 8630720 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 measurement at the end of the double-blind period
Number of subjects: 96
Study 1294818 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment administered during RA remission
Number of subjects: 94
Study 6199450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (maximum dose)
Number of subjects: 5
Study 30615671 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 0
Study 30615671 — intervention group
Group type: COMPARATOR
Intervention: Former and never smokers
Number of subjects: 0
Study 29661916 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with real-time continuous glucose monitoring (RT-CGM)
Number of subjects: 96
Study 29661916 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily injections (MDIs) with self-monitoring of blood glucose (SMBG)
Number of subjects: 96
Study 26372077 — intervention group
Group type: EXPERIMENTAL
Intervention: drawMD APP-aided pre-operative anesthesia education
Number of subjects: 0
Study 26372077 — intervention group
Group type: COMPARATOR
Intervention: standard verbal education
Number of subjects: 0
Study 25886108 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg with dexamethasone 8 mg
Number of subjects: 75
Study 25886108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with dexamethasone 8 mg
Number of subjects: 75
Study 25886108 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg alone (Control Group)
Number of subjects: 75
Study 25886108 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Granisetron, Ondansetron, Dexamethasone)
Number of subjects: 75